company background image
SLN

Silence TherapeuticsAIM:SLN Stock Report

Market Cap

UK£484.8m

7D

-1.7%

1Y

29.2%

Updated

29 Nov, 2021

Data

Company Financials +
SLN fundamental analysis
Snowflake Score
Valuation0/6
Future Growth1/6
Past Performance0/6
Financial Health6/6
Dividends0/6

SLN Stock Overview

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications.

Price History & Performance

Summary of all time highs, changes and price drops for Silence Therapeutics
Historical stock prices
Current Share PriceUK£5.35
52 Week HighUK£6.80
52 Week LowUK£4.11
Beta1.18
1 Month Change5.94%
3 Month Change-7.60%
1 Year Change29.23%
3 Year Change474.65%
5 Year Change393.09%
Change since IPO-78.81%

Recent News & Updates

Aug 20
These Analysts Think Silence Therapeutics plc's (LON:SLN) Earnings Are Under Threat

These Analysts Think Silence Therapeutics plc's (LON:SLN) Earnings Are Under Threat

Today is shaping up negative for Silence Therapeutics plc ( LON:SLN ) shareholders, with the analysts delivering a...

Shareholder Returns

SLNGB BiotechsGB Market
7D-1.7%-2.4%-1.9%
1Y29.2%24.4%13.8%

Return vs Industry: SLN exceeded the UK Biotechs industry which returned 24.6% over the past year.

Return vs Market: SLN exceeded the UK Market which returned 11.6% over the past year.

Price Volatility

Is SLN's price volatile compared to industry and market?
SLN volatility
SLN Average Weekly Movement5.9%
Biotechs Industry Average Movement5.9%
Market Average Movement4.9%
10% most volatile stocks in GB Market9.7%
10% least volatile stocks in GB Market2.6%

Stable Share Price: SLN is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: SLN's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a65Mark Rotherahttps://www.silence-therapeutics.com

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company’s platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body’s natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell.

Silence Therapeutics Fundamentals Summary

How do Silence Therapeutics's earnings and revenue compare to its market cap?
SLN fundamental statistics
Market CapUK£484.84m
Earnings (TTM)-UK£42.42m
Revenue (TTM)UK£11.35m

42.3x

P/S Ratio

-11.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SLN income statement (TTM)
RevenueUK£11.35m
Cost of RevenueUK£6.85m
Gross ProfitUK£4.50m
ExpensesUK£46.92m
Earnings-UK£42.42m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.47
Gross Margin39.67%
Net Profit Margin-373.84%
Debt/Equity Ratio0%

How did SLN perform over the long term?

See historical performance and comparison

Valuation

Is Silence Therapeutics undervalued compared to its fair value and its price relative to the market?

29.36x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: SLN (£5.35) is trading above our estimate of fair value (£0.07)

Significantly Below Fair Value: SLN is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: SLN is unprofitable, so we can't compare its PE Ratio to the UK Biotechs industry average.

PE vs Market: SLN is unprofitable, so we can't compare its PE Ratio to the UK market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SLN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SLN is overvalued based on its PB Ratio (29.4x) compared to the GB Biotechs industry average (6.3x).


Future Growth

How is Silence Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

-18.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SLN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SLN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SLN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SLN's revenue (10% per year) is forecast to grow faster than the UK market (4.9% per year).

High Growth Revenue: SLN's revenue (10% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: SLN is forecast to be unprofitable in 3 years.


Past Performance

How has Silence Therapeutics performed over the past 5 years?

-40.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SLN is currently unprofitable.

Growing Profit Margin: SLN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SLN is unprofitable, and losses have increased over the past 5 years at a rate of 40.2% per year.

Accelerating Growth: Unable to compare SLN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SLN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (50.7%).


Return on Equity

High ROE: SLN has a negative Return on Equity (-259.27%), as it is currently unprofitable.


Financial Health

How is Silence Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: SLN's short term assets (£83.1M) exceed its short term liabilities (£18.4M).

Long Term Liabilities: SLN's short term assets (£83.1M) exceed its long term liabilities (£58.0M).


Debt to Equity History and Analysis

Debt Level: SLN is debt free.

Reducing Debt: SLN has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable SLN has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: SLN is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 21.2% per year.


Dividend

What is Silence Therapeutics's current dividend yield, its reliability and sustainability?

0.062%

Forecast Dividend Yield


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SLN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SLN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SLN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SLN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SLN's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.0yrs

Average management tenure


CEO

Mark Rothera (58 yo)

1.17yrs

Tenure

UK£521,228

Compensation

Mr. Mark Andrew Rothera is President, Chief Executive Officer and Executive Director of Silence Therapeutics plc since September 14, 2020. Mr. Rothera has experience in the biopharmaceutical industry, with...


CEO Compensation Analysis

Compensation vs Market: Mark's total compensation ($USD693.39K) is below average for companies of similar size in the UK market ($USD1.03M).

Compensation vs Earnings: Insufficient data to compare Mark's compensation with company performance.


Leadership Team

Experienced Management: SLN's management team is not considered experienced ( 2 years average tenure), which suggests a new team.


Board Members

Experienced Board: SLN's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.2%.


Top Shareholders

Company Information

Silence Therapeutics plc's employee growth, exchange listings and data sources


Key Information

  • Name: Silence Therapeutics plc
  • Ticker: SLN
  • Exchange: AIM
  • Founded: NaN
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£484.837m
  • Shares outstanding: 89.78m
  • Website: https://www.silence-therapeutics.com

Number of Employees


Location

  • Silence Therapeutics plc
  • 72 Hammersmith Road
  • London
  • Greater London
  • W14 8TH
  • United Kingdom

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/11/29 22:51
End of Day Share Price2021/11/29 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.